Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
OptimizeRx
(NASDAQ:OPRX)
Intraday
$10.12
1.32
[15.00%]
After-Hours
$10.12
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$10.12
1.32
[15.00%]
At close: Apr 26
$10.12
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for OptimizeRx Stock (NASDAQ:OPRX)
OptimizeRx Stock (NASDAQ: OPRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 26, 2024
OptimizeRx Corporation Says 1Q24 Revenue Expected To Grow Over 40% YoY And Come In Between $18.5M-$19.2M Vs. $17.03M Estimate; Company Says DAAP Adoption And Cross Selling Activities Are Tracking Ahead Of Internal Expectations
Benzinga Newsdesk
-
16 hours ago
Tuesday, April 16, 2024
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $15 Price Target
Benzinga Newsdesk
-
Apr 16, 2024, 11:18AM
OptimizeRx Sees FY24 Revenue Of $100M Vs. $104.73M Est.
Benzinga Newsdesk
-
Apr 16, 2024, 7:08AM
OptimizeRx Q4 Adj EPS $0.26, Inline, Sales $28.40M Beat $26.47M Estimate
Benzinga Newsdesk
-
Apr 16, 2024, 7:06AM
Thursday, April 04, 2024
JMP Securities Initiates Coverage On OptimizeRx with Market Outperform Rating, Announces Price Target of $15
Benzinga Newsdesk
-
Apr 4, 2024, 5:02AM
Monday, April 01, 2024
Where OptimizeRx Stands With Analysts
Benzinga Insights
-
Apr 1, 2024, 2:00PM
Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target
Benzinga Newsdesk
-
Apr 1, 2024, 11:05AM
RBC Capital Reiterates Outperform on OptimizeRx, Maintains $17 Price Target
Benzinga Newsdesk
-
Apr 1, 2024, 9:50AM
Thursday, March 28, 2024
Earnings Scheduled For March 28, 2024
Benzinga Insights
-
Mar 28, 2024, 5:24AM
Wednesday, March 27, 2024
OptimizeRx Earnings Preview
Benzinga Insights
-
Mar 27, 2024, 1:01PM
Tuesday, March 12, 2024
OptimizeRx shares are trading lower. The company reaffirmed its FY23 revenue guidance.
Benzinga Newsdesk
-
Mar 12, 2024, 12:59PM
Monday, March 11, 2024
OptimizeRx Reaffirms Prior Revenue In The Range Of $68M-$70M Vs $69.85M Est. And Adjusted EBITDA Estimates For FY2023
Happy Mohamed
-
Mar 11, 2024, 4:35PM
Wednesday, January 10, 2024
RBC Capital Maintains Outperform on OptimizeRx, Raises Price Target to $17
Benzinga Newsdesk
-
Jan 10, 2024, 10:03AM
Tuesday, January 09, 2024
OptimizeRx shares are trading higher after the company reported preliminary FY23 revenue guidance.
Benzinga Newsdesk
-
Jan 9, 2024, 11:53AM
OptimizeRx Says Prelim, 2023 Revenue Is Expected To Exceed Guidance Range Of $68M-$70M
Benzinga Newsdesk
-
Jan 9, 2024, 7:33AM
Wednesday, January 03, 2024
Barclays Initiates Coverage On OptimizeRx with Equal-Weight Rating, Announces Price Target of $15
Benzinga Newsdesk
-
Jan 3, 2024, 5:41AM
Monday, November 06, 2023
OptimizeRx shares are trading higher after the company issued strong FY23 guidance.
Benzinga Newsdesk
-
Nov 6, 2023, 11:49AM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Nov 6, 2023, 8:06AM
OptimizeRx Expects FY23 Revenues To Be Between $68M-$70M Vs. Consensus Of $60.51M; And Adjusted EBITDA Of $3M-$4M
Benzinga Newsdesk
-
Nov 6, 2023, 7:19AM
OptimizeRx Q3 Adj EPS $0.09 Up From $0.07 YoY, Sales $16.33M Beat $15.01M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 7:01AM
Friday, November 03, 2023
A Preview Of OptimizeRx's Earnings
Benzinga Insights
-
Nov 3, 2023, 4:00PM
Thursday, October 12, 2023
Digital Health Tech OptimizeRx's Acquisition of Medicx Health To Boost Earnings And Market Potential: Analyst
Vandana Singh
-
Oct 12, 2023, 1:42PM
Why InMode Shares Are Trading Lower By 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Oct 12, 2023, 12:55PM
OptimizeRX Announces Preliminary Results, Discloses An Agreement To Acquire Medicx Health For $95M
Benzinga Newsdesk
-
Oct 12, 2023, 7:05AM
Thursday, August 24, 2023
OptimizeRx Expands AI Powered Omnichannel Platform
Benzinga Newsdesk
-
Aug 24, 2023, 8:12AM
Wednesday, August 23, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Aug 23, 2023, 1:16PM
Tuesday, August 22, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 22, 2023, 1:51PM
Tuesday, August 15, 2023
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Aug 15, 2023, 2:01PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 15, 2023, 1:31PM
OptimizeRx Corporation shares are trading lower after the company reported worse-than-expected Q2 revenue results. Additionally, multiple firms lowered their respective price targets on the stock.
Benzinga Newsdesk
-
Aug 15, 2023, 11:34AM
RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $14
Benzinga Newsdesk
-
Aug 15, 2023, 11:29AM
Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $13
Benzinga Newsdesk
-
Aug 15, 2023, 11:08AM
Roth MKM Maintains Buy on OptimizeRx, Lowers Price Target to $20
Benzinga Newsdesk
-
Aug 15, 2023, 11:06AM
B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $18
Benzinga Newsdesk
-
Aug 15, 2023, 11:01AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Aug 15, 2023, 9:06AM
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $13
Benzinga Newsdesk
-
Aug 15, 2023, 8:20AM
Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Aug 15, 2023, 8:17AM
Monday, August 14, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Aug 14, 2023, 5:32PM
OptimizeRx Q2 EPS $(0.01) Beats $(0.02) Estimate, Sales $13.82M Miss $14.81M Estimate
Benzinga Newsdesk
-
Aug 14, 2023, 4:02PM
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
Wednesday, May 24, 2023
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
May 24, 2023, 12:48PM
Wednesday, May 10, 2023
Recap: OptimizeRx Q1 Earnings
Benzinga Insights
-
May 10, 2023, 4:20PM
OptimizeRx Q1 Adj EPS $(0.09) Misses $(0.08) Estimate, Sales $13.00M Beat $12.35M Estimate
Benzinga Newsdesk
-
May 10, 2023, 4:02PM
Earnings Scheduled For May 10, 2023
Benzinga Insights
-
May 10, 2023, 9:12AM
Tuesday, May 09, 2023
OptimizeRx Earnings Preview
Benzinga Insights
-
May 9, 2023, 2:01PM
Thursday, March 16, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Mar 16, 2023, 2:14PM
Tuesday, March 14, 2023
OptimizeRx shares are trading higher after the company announced a $15 million share repurchase program.
Michael Horton
-
Mar 14, 2023, 10:57AM
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Lisa Levin
-
Mar 14, 2023, 8:02AM
OptimizeRx Authorizes $15M Share Repurchase Program
Bill Haddad
-
Mar 14, 2023, 7:44AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch